All News

The event featured expert-led sessions, networking, and recognition for technicians’ outstanding contributions.

The FDA approves guselkumab, the first IL-23 inhibitor for pediatric psoriasis and psoriatic arthritis, enhancing treatment options for children.

Patients with newly diagnosed transplant-eligible multiple myeloma (NDTE-MM) had high rates of complete response and minimal residual disease–negativity.

A meta-analysis found that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors induce sustained reductions across lipid biomarkers, including low-density lipoprotein cholesterol (LDL-C).

Anitocabtagene autoleucel shows impressive efficacy and safety in treating relapsed/refractory multiple myeloma, achieving a 97% overall response rate.

Pharmacists play a crucial role in managing drug interactions and optimizing treatment with CDK4/6 inhibitors for HER2-positive breast cancer patients.

Biolinq Shine, a wearable biosensor, revolutionizes diabetes management with real-time glucose, activity, and sleep tracking.

Pediatric flu cases surge, revealing alarming rates of encephalopathy.

Xavier Leleu, MD, PhD, shares how OBI technology reduces preparation time and manual pushes for pharmacists.

Young, non-diabetic individuals were most likely to delay statin initiation for low-density lipoprotein cholesterol (LDL-C) lowering, increasing their risk of myocardial infarction.

Paltusotine, the first oral treatment for acromegaly, offers hope for improved patient care and management.

Individuals with heart failure who are Black, Hispanic, or Asian face a much earlier onset of heart failure hospitalization compared with White patients.

Interim trial data presented at the 2025 World Conference on Lung Cancer shows pumitamig’s promising efficacy in patients with extensive stage small cell lung cancer (ES-SCLC).

Pharmacists enhance patient care by managing CDK4/6 inhibitors, addressing adverse effects and ensuring effective therapy selection in oncology.

The approval is supported by clinical findings from the EMBER-3 trial.

Expert shares the evolving role of pharmacy in patient care, emphasizing treatment accessibility and monitoring.

In a dose-escalation portion of LINKER-MM4, linvoseltamab monotherapy demonstrated a high overall response rate (ORR) and minimal residual disease (MRD) negativity in both transplant-eligible and transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).

The authors wrote that patients with CKD under the age of 60 years may be at a greater risk of depression.

New IMWG/IMS guidelines enhance risk assessment for multiple myeloma, revealing daratumumab's impact on patient outcomes in real-world settings.

Using the United States Vaccine Adverse Event Reporting System database, investigators found that pneumococcal vaccination led to predominantly nonserious adverse events.

Recent studies reveal that simvastatin does not enhance escitalopram's effects in treating depression, despite improving metabolic health in obese patients.

Pharmacists learn to recognize and combat burnout through self-awareness, open dialogue, and supportive workplace strategies for lasting well-being.

Pharmacists navigate the evolving hematology-oncology landscape, utilizing genetic insights and innovative therapies to enhance patient care.

New research links rapid CAR T-cell expansion to delayed neurotoxicity in patients with multiple myeloma.

Pharmacists enhance food safety by identifying foodborne illness symptoms, especially as FoodNet narrows its focus on E coli and Salmonella.

Claudio Cerchione, MD, PhD, discusses the benefits of anti-CD38 quadruplet regimens for older patients with multiple myeloma.

New intravenous formulation GTx-104 shows promise in improving brain health outcomes for patients with aSAH, offering safer treatment options for pharmacists.